Efficacy of dupilumab on chronic rhinosinusitis with nasal polyps and concomitant asthma in biologic-naive and biologic-pretreated patients

Objectives Dupilumab, an anti-IL-4 receptor monoclonal antibody (mAb), was recently approved for the treatment of severe chronic rhinosinusitis with nasal polyps (CRSwNP). The main objective of this study was to assess whether previous exposure to biological treatment affected the clinical outcomes...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	María Sandra Domínguez-Sosa, María Soledad Cabrera-Ramírez, Miriam del Carmen Marrero-Ramos, Delia Dávila-Quintana, Carlos Cabrera-López, Heleia González Cuervo, Jesús Javier Benítez del Rosario, Teresa Carrillo-Díaz
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Taylor & Francis Group 2024-12-01
Цуврал:	Annals of Medicine
Нөхцлүүд:	Chronic rhinosinusitis nasal polyps dupilumab monoclonal antibody perennial allergen sensitization
Онлайн хандалт:	https://www.tandfonline.com/doi/10.1080/07853890.2024.2411018
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!